Next Article in Journal
Delivering Positive Newborn Screening Results: Cost Analysis of Existing Practice versus Innovative, Co-Designed Strategies from the ReSPoND Study
Next Article in Special Issue
Newborn Screening for X-Linked Adrenoleukodystrophy: Review of Data and Outcomes in Pennsylvania
Previous Article in Journal
Towards Next-Generation Sequencing (NGS)-Based Newborn Screening: A Technical Study to Prepare for the Challenges Ahead
Previous Article in Special Issue
Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future
 
 
Review
Peer-Review Record

Monitoring for and Management of Endocrine Dysfunction in Adrenoleukodystrophy

Int. J. Neonatal Screen. 2022, 8(1), 18; https://doi.org/10.3390/ijns8010018
by Isha Kachwala 1 and Molly O. Regelmann 2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Neonatal Screen. 2022, 8(1), 18; https://doi.org/10.3390/ijns8010018
Submission received: 31 December 2021 / Revised: 10 February 2022 / Accepted: 10 February 2022 / Published: 2 March 2022
(This article belongs to the Special Issue Newborn Screening and Follow-Up for X-ALD)

Round 1

Reviewer 1 Report

This is a well- written review. 

Author Response

Thank you to reviewer #1. Please see response to reviewer #2 for minor edits.

Reviewer 2 Report

The manuscript by Drs. Kachwala and Regelmann reviews the endocrine disease in X-ALD and provides recommendations for monitoring and treating adrenal insufficiency. The manuscript is well written and thoroughly covers the topic. The algorithm figure for assessing adrenal insufficiency is reprinted from a prior publication and is a welcome addition to the manuscript. It was nice to see a section on testicular dysfunction, which is often ignored in other reviews on this disease. Also, the authors bring up the quality of hormone test methods, not before raised in the X-ALD literature. Overall, I have no significant criticism of the manuscript, which looks acceptable with only minor typographical corrections.

  1. Page 2, line 61: Should read “VLCFA-containing cholesterol esters”.
  2. Page 2, line 66: delete “because”.
  3. Page 7, line 232: Replace “prevent” with “delay”.

Author Response

We appreciate the thoughtful response from reviewer #2. We have made the recommended edits to correct the typographical/language errors.

  1. Page 2, line 61: Now reads: “VLCFA-containing cholesterol esters”.
  2. Page 2, line 66: We deleted “because”.
  3. Page 7, line 232: We replaced “prevent” with “delay”.
Back to TopTop